Items Tagged ‘Minnesota news release’
Posted on March 3rd, 2014 by Sharon Theimer
New York — March 3, 2014 — A new approach to breast reconstruction surgery aimed at helping patients’ bodies get back to normal more quickly cut their postoperative opioid painkiller use in half and meant a day less in the hospital on average, a Mayo Clinic study found. The method includes new pain control techniques, preventive anti-nausea treatment and getting women eating and walking soon after free flap breast reconstruction surgery. It has proved so effective, it is now being used across plastic surgery at Mayo Clinic. The findings were being presented at the Plastic Surgery Research Council annual meeting March 7-9 in New York.
Breast reconstruction surgery is common after breast tissue is removed to prevent or treat breast cancer; in free flap breast reconstruction, the plastic surgeon transfers a section of tissue from one part of the body to the chest. Using traditional care, the hospital stay averaged roughly four and a half days after that procedure. Using a new approach known as an “enhanced recovery pathway,” patients spent an average of three days in the hospital, the researchers found.
Opioid painkiller use by patients in the hospital after surgery also declined with the new method, and those patients reported less pain at 24 hours after surgery than those who received the traditional approach. Calculated in oral morphine equivalents, opioid use averaged 142.3 milligrams over the first three days in the hospital, compared with an average of 321.3 milligrams over the same period with traditional care.
Posted on February 27th, 2014 by Ginger Plumbo
ROCHESTER, Minn. — Feb. 27, 2014 — Here are highlights from the February issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. Include the following subscription information as your editorial policies permit: Visit http://www.HealthLetter.MayoClinic.com or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text: Mayo Clinic Health Letter February 2014 (for journalists only). Full special report text: Mayo Clinic Health Letter Special Report February 2014 (for journalists only).
Older adults often report a good night’s sleep is hard to come by. In an eight-page Special Report on sleep, the February issue of Mayo Clinic Health Letter covers changes in sleep that can occur with aging and how to get better sleep without taking pills.
Poor sleep isn’t an inevitable part of aging. Yet, older adults are twice as likely to be prescribed a sedative medication for insomnia as are young adults. These medications ― zolpidem (Ambien, others), eszopiclone (Lunesta) or zaleplon (Sonata) ― aren’t meant to be used beyond four to eight weeks. Many older adults use them for months or years even though these medications can cause unwanted side effects including residual sleepiness during the day, dizziness, lightheadedness and mental impairment.
Mayo Clinic Health Letter covers several nondrug approaches and strategies that have proved to help relieve insomnia. Strategies include:
Exercise: Evidence shows that incorporating regular exercise into the daily routine improves sleep. Exercise increases the amount of energy expended, and the amounts of “feel-good” hormones (endorphins) the body produces. Both are likely to lead to better sleep. Read the rest of this entry »
Posted on February 27th, 2014 by Sharon Theimer
Patients with dental extractions before cardiac surgery still at risk for poor outcomes, study finds
Rochester, Minn. — Feb. 27, 2014 — To pull or not to pull? That is a common question when patients have the potentially dangerous combination of abscessed or infected teeth and the need for heart surgery. In such cases, problem teeth often are removed before surgery, to reduce the risk of infections including endocarditis, an infection of the inner lining of the heart that can prove deadly. But Mayo Clinic research suggests it may not be as simple as pulling teeth: The study found that roughly 1 in 10 heart surgery patients who had troublesome teeth extracted before surgery died or had adverse outcomes such as a stroke or kidney failure.
The findings are published in The Annals of Thoracic Surgery.
Prosthetic heart valve-related endocarditis accounts for up to one-fourth of infective endocarditis cases and proves fatal for up to 38 percent of patients who develop it. In light of that high mortality rate, physicians try to address risk factors such as poor dental health before cardiac surgery. Removing diseased teeth at some point before surgery as a preventive measure is common, but research on whether that helps has been limited. Medical guidelines acknowledge a lack of conclusive evidence, the Mayo researchers noted.
The new study shows that the risk for patients who do have teeth removed before heart surgery “may be higher than we thought,” says senior author Kendra Grim, M.D., a Mayo Clinic anesthesiologist.
“We are always concerned with improving safety, and pulling infected teeth before heart surgery seemed to be the safer intervention. But we became interested in studying this complex patient group, as many patients that come to the operating room for dental surgery just before heart surgery are quite ill,” Dr. Grim says.
The study is believed to be the largest so far evaluating adverse outcomes after pre-cardiac surgery dental extractions. The researchers studied outcomes in 205 adult Mayo patients who had teeth pulled before cardiovascular surgery. The study covered January 1, 2003, through Feb. 28, 2013; 80 percent of the patients were men, the median age at the time of tooth extraction was 62, and the median time lapse between dental extraction and heart surgery was seven days. The research found:
More information is needed to understand why patients died or had other major adverse outcomes, the researchers say. In addition to the stress placed on the body by dental extraction and heart surgery themselves, potential factors include the severity of individual patients’ heart disease, other serious health problems they may have had, and how they reacted to anesthesia.
The bottom line for patients and physicians, the researchers conclude: Rather than following a rule of thumb, physicians should evaluate each patient individually to weigh the possible benefit of tooth extraction before heart surgery against the risk of death and other major adverse events.
“We hope this study sparks future discussion and research,” Dr. Grim says. “In the meantime, we recommend an individualized approach for these patients, to weigh their particular risk and benefit of a dental procedure before cardiac surgery with the information we have currently available.”
The study was funded by Mayo Clinic. The first author is Mark M. Smith, M.D., a Mayo anesthesiologist. The co-authors are anesthesiologists David Barbara, M.D., and William Mauermann, M.D.; Christopher Viozzi, D.D.S., M.D., an oral and maxillofacial surgeon; and cardiovascular surgeon Joseph Dearani, M.D., all of Mayo Clinic.
About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, MayoClinic.org or http://newsnetwork.mayoclinic.org/.
Posted on February 26th, 2014 by Karl W Oestreich
ROCHESTER, Minn. — Feb. 26, 2014 — As Mayo Clinic recognizes its Sesquicentennial year, the not-for-profit organization reached a record 63 million people in 2013. The strong performance was bolstered by successful implementation of new care delivery models — such as the Mayo Clinic Care Network — that provide knowledge to patients, physicians and consumers in traditional and new ways.
“Expanding our reach is not a new goal for us,” says John Noseworthy, M.D., Mayo Clinic president and CEO. “In fact, as we consider our history, growth has been a constant for 150 years.”
Posted on February 24th, 2014 by Karl W Oestreich
WHAT:An opportunity to ask questions about Mayo Clinic’s 2013 performance.
John Noseworthy, M.D.
President and CEO, Mayo Clinic
Vice President, Administration and CAO, Mayo Clinic
Noon CST/1 p.m. EST
Wednesday, Feb. 26, 2014
Audio news conference
Read the rest of this entry »
Posted on February 24th, 2014 by Sam Smith
ROCHESTER, Minn. — Feb. 24, 2014 — Mayo Clinic researchers have fashioned a new key to unlocking the secrets of the human genome. The Binary Indexing Mapping Algorithm, version 3 (BIMA V3) is a freely available computer algorithm that identifies alterations in tumor genomes up to 20 times faster and with 25 percent greater accuracy than other popular genomic alignment programs. BIMA results are published this month in the journal Bioinformatics.
Journalists: Sound bites with Dr. Vasmatzis are available in the downloads.
BIMA is a next-generation sequencing mapping and alignment algorithm, customized to process mate pair library sequencing. Mate pair sequencing is a comprehensive and cost-effective method for detecting changes throughout the entire genome.
“BIMA allows us to evaluate tumor genomes in a fraction of the time it takes many popular technologies,” says George Vasmatzis, Ph.D., a Mayo Clinic molecular biologist, director of the Biomarker Discovery Program in the Mayo Clinic Center for Individualized Medicine, and senior author of the paper. “We believe this tool will lead to a better understanding of tumor genomics, and ultimately better therapy for patients with cancer.” Read the rest of this entry »
Posted on February 24th, 2014 by Joe Dangor
ROCHESTER, Minn. — Feb. 24, 2014 — Blacks may be twice as likely as whites to develop multiple myeloma because they are more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance (MGUS), a Mayo Clinic study has found. Not only is MGUS more common in blacks, but the type seen in the black population is also more apt to have features associated with a higher risk of progression to full-blown multiple myeloma, a cancer of a type of white blood cell in bone marrow.
Posted on February 21st, 2014 by Karl W Oestreich
PHOENIX — Feb. 21, 2014 — The Mayo Clinic Board of Trustees welcomed Samuel A. Di Piazza, Jr. as the new board chair and George Halvorson as a new member, recognized five retiring public members and three internal members who completed their tenure, and elected four new internal trustees.
Di Piazza replaces Marilyn Carlson Nelson, who is retiring from the board. Di Piazza recently announced that he was leaving Citi as vice chairman and a member of the Senior Client Executive Group to serve as Mayo Clinic’s Board of Trustees chair. Di Piazza joined the Mayo board in 2010. He joined Citi in May 2011 after a long career at PricewaterhouseCoopers as a partner and, ultimately, CEO from 2002 through 2009.
Posted on February 18th, 2014 by Joe Dangor
ROCHESTER, Minn. — Feb. 18, 2014 — Newly-diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years after diagnosis have essentially the same life expectancy as they did prior to diagnosis, a Mayo Clinic study has found. Cancer related outcome events include disease progression or relapse, need for re-treatment or death.
Journalists: Sound bites with lead author Matthew Maurer are available in the downloads.
Results of the study appear in the Journal of Clinical Oncology. The findings indicate that the 24-month mark is a significant milestone that can be used both as an effective way to counsel patients on their long-term prognosis and as an earlier endpoint for future studies of newly diagnosed DLBCL.
Posted on February 11th, 2014 by Sam Smith
Study targets EGFR and FGFR cellular pathways to treat rare disease
SCOTTSDALE, Ariz. — Feb. 13, 2014 — Physicians at Mayo Clinic’s Center for Individualized Medicine and researchers at the Translational Genomics Research Institute (TGen) have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies. Potential new treatment approaches are being validated to develop new tests that physicians can use to guide therapy for this aggressive cancer of the bile ducts that progresses quickly and is difficult to treat.
Clinically important findings suggest that targeting the epidermal growth factor receptor (EGFR) and the fibroblast growth factor receptor (FGFR) cellular pathways may benefit thousands of patients with this disease, according to the study published today in the journal PLOS Genetics.
Half of the patients treated in this study responded to either ponatinib (typically used for certain types of leukemia) or pazopinib (a kidney cancer drug), depending on the genetic alterations identified through sequencing.
“In 3 out of the 6 patients we analyzed, we found compelling, treatable and unexpected genetic alterations that would never have been found by normal testing methods for cholangiocarcinoma,” says Mitesh Borad, M.D., a Mayo Clinic oncologist and lead author of the paper. “We treated these three patients with drugs that attack these genetic alterations and saw tumor shrinkage. This gives us hope for better treatments for this aggressive, hard-to-treat cancer.”
Because of these encouraging early results, the team of 49 doctors and researchers proposes large-scale clinical trials to test EFGR and FGFR inhibitors as possible treatments for biliary tract cancers that harbor mutations in these genes and pathways.
“Our results demonstrate that if we find the right molecular context, more appropriate therapies can be chosen that improve outcomes,” says John Carpten, Ph.D., TGen deputy director of basic science and director of TGen’s Integrated Cancer Genomics Division, and the study’s senior author. “We now hope to design larger clinical studies to treat patients’ tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit for patients with primary or advanced cholangiocarcinoma.”
Bile duct cancer is a rare cancer that occurs mostly in people older than age 50. Surgical approaches, such as resection and liver transplantation, represent the only curative treatment approaches, says Dr. Borad. Most patients, however, present with surgically unresectable or metastatic disease at the time of diagnosis. Standard-of-care chemotherapies are not curative and there is an unmet need for newer approaches, Dr. Borad adds.
# # #
About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, http://www.mayoclinic.org and newsnetwork.mayoclinic.org.
About the Mayo Clinic Center for Individualized Medicine
The Mayo Clinic Center for Individualized Medicine is home to the Individualized Medicine Clinic, the world’s first integrated, multidisciplinary genomics clinic, serving patients with advanced cancer and complex diagnoses. The center discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient. Visit http://mayoresearch.mayo.edu/center-for-individualized-medicine for more information.
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: http://www.tgen.org